Surface Oncology Inc. (NASDAQ:SURF) and Anika Therapeutics Inc. (NASDAQ:ANIK) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.
Earnings and Valuation
Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.
Profitability
Table 2 hightlights the net margins, return on assets and return on equity of the two companies.
Liquidity
The Current Ratio of Surface Oncology Inc. is 11.3 while its Quick Ratio stands at 11.3. The Current Ratio of rival Anika Therapeutics Inc. is 18.1 and its Quick Ratio is has 16.1. Anika Therapeutics Inc. is better equipped to clear short and long-term obligations than Surface Oncology Inc.
Analyst Recommendations
The Recommendations and Ratings for Surface Oncology Inc. and Anika Therapeutics Inc. are featured in the next table.
On the other hand, Anika Therapeutics Inc.s potential downside is -18.53% and its average target price is $55.
Institutional and Insider Ownership
Roughly 71.6% of Surface Oncology Inc. shares are held by institutional investors while 96.6% of Anika Therapeutics Inc. are owned by institutional investors. Insiders held roughly 0.2% of Surface Oncology Inc.s shares. Competitively, 0.9% are Anika Therapeutics Inc.s share held by insiders.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
For the past year Surface Oncology Inc. has -47.88% weaker performance while Anika Therapeutics Inc. has 63.91% stronger performance.
Summary
Anika Therapeutics Inc. beats Surface Oncology Inc. on 10 of the 12 factors.
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company's lead product candidate is the SRF231 that is in Phase I clinical trial targeting protein called cluster of differentiation (CD) 47. It is also developing SRF373 inhibiting CD73; SRF617 inhibiting CD39; and SRF388, an antibody targeting interleukin 27. The company has a collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The companys dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
Read more from the original source:
Comparing of Surface Oncology Inc. (SURF) and Anika Therapeutics Inc. (NASDAQ:ANIK) - MS Wkly